Shots:
- AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseases
- As per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvals
- CPTX2309 is a tLNP delivering mRNA for anti-CD19 CAR to CD8+ T cells in vivo, aiming to treat B cell-mediated autoimmune diseases
Ref: AbbVie | Image: Capstan Therapeutics | Press Release
Related News:- AbbVie Reports Topline P-III (TEMPLE) Trial Data on Qulipta (Atogepant) for Migraine Prevention
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
